Saturday, October 3, 2026
23.1 C
Bengaluru

IMS Health Market Reflection Report for September 2016

IMS

Every month, MedicinMan in partnership with IMS Health, brings our readers the latest industry numbers related to sales and revenues of the top companies, brands and therapy areas in the Indian Pharmaceutical Market.

The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.

[su_dropcap style="flat" size="3" class=""]T[/su_dropcap]he Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

With over three decades of experience in the pharmaceutical...

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

India’s anaemia challenge is not simply about access to...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing...

Topics

Why Is the World’s Pharmacy Failing to Protect Patients from Harm?

This MedicinMan Intelligence Report follows a disturbing trail—from Arun...

10 Years of Pharma M&A — Who’s Really Benefited?

Pharmaceutical M&A is usually discussed in the language of...

What’s Killing Patients? Cancer or Rigged Drug Prices?

The disease is real. So is the markup. Confusing...

A Tale of Two Cities: Peptides and Prescriptions

What our health choices reveal about education, access and...

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

MedicinMan Intelligent Insights When Air India CEO Tewolde Gebremariam...
spot_img

Related Articles

spot_imgspot_img
Previous article
Next article